PROK biotech catalysts & pipeline

PROKIDNEY CORP · Data as of 2026-09-08

Upcoming catalysts

rilparencel — Topline data

Q2 2027

We anticipate topline data readout of the surrogate endpoint (eGFR slope) in the second quarter of 2027 and anticipate topline data readout of the confirmatory endpoint (composite time-to-event) in the second half of 2029.

Source filing

rilparencel — NDA/BLA submission

Q4 2027

Q4 2027 : BLA submission of rilparencel

Source filing

rilparencel — Topline data

H2 2029

We anticipate topline data readout of the surrogate endpoint (eGFR slope) in the second quarter of 2027 and anticipate topline data readout of the confirmatory endpoint (composite time-to-event) in the second half of 2029.

Source filing

rilparencel — Conference presentation

FY 2026

Throughout FY 2026 : Present results from ongoing mechanism of action studies of rilparencel at medical and scientific conferences

Source filing

Explore the free biotech catalyst calendar